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Introduction
Bone marrow stromal cells (MSCs) are stem cells from the adult marrow that can give rise to both mesenchymal and non-mesenchymal lineages. MSCs provide feeder layers for cultures of hematopoietic precursors and can differentiate into osteoblasts, adipocytes, and myoblasts. [1] [2] [3] [4] To a limited degree, MSCs may also migrate through the blood-brain barrier to contribute to lineages of the CNS when transplanted systemically. 5, 6 Recently, the versatility of MSCs was further revealed by the observation that MSCs can generate cell lineages of the CNS. For example, murine MSCs transplanted into the paraventricular zone of neonatal mice displayed the markers, glial fibrillary acidic protein (GFAP) and neurofilament-L, indicative of differentiation to both astrocytes and neurons, respectively. 7 In another study, rat MSCs that were injected intravenously into rats subjected to a traumatic brain injury migrated to the area of injured brain after 15 days, and some donor MSCs expressed the neuronal marker NeuN. 8 In vitro, as many as 80% of MSCs exhibited characteristics of neurons when incubated with a cocktail of antioxidants in the absence of serum. 9 In another study, adult human and murine MSCs incubated with retinoic acid and brain-derived neurotrophic factor (BDNF) or co-cultured with fetal mesencephalic cells Therefore, MSCs appear to be useful cells to transplant into the CNS and either deliver therapeutic molecules or replace CNS cells that have been lost in a neurodegenerative process.
For the treatment of Parkinson's disease (PD), the mainstay of therapy is oral administration of L-3,4,-dihydroxyphenyalanine (L-DOPA). However, the effectiveness is variable among patients and decreases with time. 11 Many in vivo and ex vivo strategies have been pursued to replace L-DOPA/dopamine in the denervated striatum. One strategy is to use viral vectors. For example, adeno-associated virus (AAV) vectors were successful in producing expression of the TH and GC genes in neurons of the striatum for up to 1 year. 12 Controlled delivery of L-DOPA was achieved by infusion into the striatum of adenovirus containing the TH gene driven by a tetracycline inducible promoter. 13 Another strategy is to use cells as vectors. Cellular gene therapy in the rat model of PD was accomplished by using primary astrocytes retrovirally transduced with the TH gene driven by the astrocyte specific promoter for GFAP.
14 Also, primary fibroblasts from rats were transduced with the genes for TH and GC and transplanted into the denervated rat striatum. 15 The fibroblasts continued to synthesize L-DOPA in vivo, but the production was short-lived. Still another strategy was to use neural stem cells differentiated into dopaminergic neurons by overexpression of the nuclear hormone receptor, Nurr1. 16 However, many of the current strategies require either direct administration of active viral vectors or the use of fetal tissue and/or cells that can only be obtained by invasive procedures. In contrast, MSCs are easily isolated from a patient's bone marrow, manipulated in culture with a trans gene, and can be transplanted back into the brain of the same patient.
In a clinical setting, it would be advantageous to provide a vast supply of donor cells while minimizing time in culture. Recently, samples of human MSCs were plated at extremely low-density (0.5-6 cells/cm 2 ) and expanded by about 50 population doublings in approximately 60 days. This novel approach to growing MSCs could produce up to 10 13 MSCs from a single aspirate in about 6 weeks. 17 Therefore, adequate numbers of MSCs can readily be obtained for most therapeutic purposes. It is important to determine whether gene-engineered MSCs can continue to express transgenes after expansion by low-density plating.
In order to understand how to best gene-engineer the MSCs to produce L-DOPA or other therapeutic products, we wanted to study the effects of various promoter elements on expression of TH and GC in the MSCs in vitro. We have previously engineered MSCs to express TH, the rate limiting enzyme in dopamine biosynthesis, and GC, the enzyme providing the tetrahydropterin cofactor for TH. 18 The gene engineered MSCs synthesized and released L-DOPA. When the MSCs that synthesized L-DOPA were transplanted into the rat model of PD, the L-DOPA was converted to dopamine metabolites, and behavioral recovery was observed; however, the ameliorative effect of transplanted MSCs was short-lived, presumably due to inactivation of transgenes introduced into the brain with retroviruses. In the experiments, MSCs were transduced sequentially with two separate retroviruses, each containing TH or GC driven by the CMV promoter. Here, we have created a 3.4 kb bicistronic construct consisting of the TH gene and GC gene separated by an internal ribosome entry site (TH-IRES-GC) to avoid the use of two separate retroviruses. We have also used a self-inactivating retroviral vector (pSIR) in which a 3′ enhancer sequence in the LTR has been deleted, the 5′-LTR is inactivated upon integration into the target cell genome, 19 and the TH-IRES-GC central construct is driven by a promoter of choice. We have engineered parallel vectors containing the GFP reporter gene as controls. In addition, we tested whether a small number of rMSCs producing L-DOPA or expressing GFP could continue to express transgenes after a massive expansion in culture by a simple low-density plating.
Results

Relative promoter strength in MSCs
To obtain an ideal vector for gene transfer into MSCs in vitro, three expression constructs consisting of either a cellular or viral promoter upstream of the reporter gene, enhanced green fluorescent protein (GFP), were prepared. The relative effectiveness of those promoters was tested in rMSCs transiently transfected by calcium phosphate precipitation. The CMV promoter was used as a strong viral promoter, and the mouse phosphoglycerate kinase-1 (PGK) promoter and human histone 4 promoter (H4) 20 were used as promoters for housekeeping genes. CMV-GFP, PGK-GFP, and H4-GFP were transiently transfected in rMSCs and the GFP signal was assayed after 72 h by either flow cytometry for GFP or with a fluGene Therapy orescent microtiter plate reader (Figure 1 ). Cultures of rMSCs transfected with CMV-GFP had the largest number of positive cells (9% GFP-positive cells). rMSCs transfected with PGK-GFP consistently expressed GFP at approximately half the values obtained with the CMV promoter (4% GFP-positive cells for the PGK promoter). rMSCs transfected with H4-GFP expressed GFP at lower levels (0.5% GFP-positive cells).
Generation of bicistronic retroviral vectors expressing both the TH and GC genes
Both the CMV and PGK promoters were able to activate GFP expression in the rMSCs; therefore, the CMV and PGK promoters were used as internal promoters in the self-inactivating retroviral constructs. To avoid the use of two separate retroviruses, a bicistronic sequence was created consisting of the TH cDNA as the first cistron, an internal ribosome entry site (IRES), 21 and GC cDNA as the second cistron (referred to as TH-IRES-GC). The 3.4 kb TH-IRES-GC construct was then subcloned into four retroviral vectors: LXSN-TIG, MSCV-TIG, pSIR-PGK-TIG and pSIR-CMV-TIG ( Figure 2 ). As a control for vector backbone and transduction efficiency, GFP was cloned into the four vectors in parallel, yielding the following vectors: LXSN-GFP, MSCV-GFP, pSIR-CMV-GFP and pSIR-PGK-GFP.
To test the retroviral constructs for GFP expression and L-DOPA production, and to generate recombinant retrovirus, vectors were transiently transfected into the Phoenix amphotropic packaging cells by calcium phosphate precipitation and analyzed for GFP expression by fluorescence microscopy (see Figure 3 ) and flow cytometry (data not shown). To test for the effectiveness of the bicistronic TH-IRES-GC construct in producing L-DOPA, transiently transfected Phoenix cells were analyzed for L-DOPA production in the media by electrochemical detection and HPLC analysis. As a control, the MSCV vector containing the TH gene alone was used in the transfection. As shown in Figure 3I , packaging cells transfected with the TH gene alone in the MSCV backbone produced 6.5 total nmols of L-DOPA in 1 h, indicating that 293 cells have some endogenous levels of GC as reported by During et al. 22 However, when Phoenix cells were transfected with TH-IRES-GC in the same vector backbone (MSCV-TIG), about 34.4 nmols of L-DOPA total were secreted into the media after 1 h, indicating the effectiveness of the bicistronic sequence and the necessity of GC. Packaging cells transfected with LXSN-TIG, pSIR-CMV-TIG and pSIR-PGK-TIG produced 21.7 nmols, 50.3 nmols and 12.8 nmols L-DOPA, respectively. Relative amounts of L-DOPA production from each vector in the Phoenix cells closely paralleled GFP expression from the same vectors in the Phoenix cells.
GFP expression in transduced rMSCs before and after low-density expansion
Recombinant retroviruses harvested from transiently transfected Phoenix cells were used to transduce rMSCs. rMSCs infected with retroviruses from pSIR-PGK-GFP, LXSN-GFP and MSCV-GFP exhibited fluorescence due to GFP expression in rMSCs before selection with the neomycin analog G418 (8-10% of cells by flow cytometry, data not shown). However, none of the rMSCs transduced with viral supernatants from pSIR-CMV-GFP exhibited detectable GFP expression. After G418 selection, stably transduced rMSCs were analyzed for GFP Transduced rMSCs were tested for their ability to continue to exhibit GFP fluorescence after expansion by lowdensity plating. rMSCs were trypsinized and plated in triplicate at 3-6 cells/cm 2 for 3-4 weeks. As shown in the right hand column of Figure 4 , transduced cells went through at least 10.5 cell doublings and increased in number at least 1400-fold. rMSCs transduced with pSIR-PGK-GFP maintained GFP expression after increasing in number 1697-fold ± 89, increased the percentage of GFP-positive cells in the culture to 92.2%, and had a similar RFI when compared with before low-density expansion. rMSCs transduced with LXSN-GFP expanded 1409-fold ± 402 at low-density, increased the percentage of GFP-positive cells (94.4%), but had a large decrease in the RFI when compared with before low-density expansion (130.2 before low-density plating and 96.3 after low-density plating). rMSCs transduced with MSCV-GFP exhibited a decrease in the percentage of GFP-positive cells Gene Therapy after low-density plating (91.6% GFP-positive), and had the lowest RFI of 9.3; cells increased in number 3182-fold ± 332. These results indicate the relatively constant expression of GFP in rMSCs transduced with pSIR-PGK-GFP when compared with standard retroviral vectors.
Figure 3 Expression of GFP and production of L-DOPA in transfected Phoenix-amphotropic packaging cells. Phoenix cells were plated in duplicate 24 h before transfection in 60 mm dishes. Transfected Phoenixamphotropic cells were visualized for GFP expression 48 h after transfection. Phase contrast microscopy of the packaging cells transfected with (a) LXSN-GFP, (c) MSCV-GFP, (e) pSIR-CMV-GFP, and (g) pSIR-PGK-GFP. Fluorescent microscopy of the same field of cells demonstrating expression of GFP (b, d, f, h). (i) L-DOPA production in packaging cells transfected with retroviral vectors containing either TH alone or the bicistronic TH-IRES-GC sequence 48 h after transfection. Cells were incubated for 1 h at 37°C in HBSS with
Long-term GFP expression in a clonal population of pSIR-transduced cells
In order to obtain cells expressing high levels of GFP in rMSCs transduced with pSIR-PGK-GFP, cells were plated at 100 cells/10-cm dish and isolated colonies were expanded. A high GFP-expressing clone was isolated from the heterogeneous population of cells and is referred to as rMSCs pSIR-PGK-GFP clone 12. As shown in Figure 5a , 93.9% of cells were positive for GFP and they exhibited a high RFI of 155.4 when compared with control cells. This clonal population of cells was tested for continued expression of GFP after low-density expansion. rMSCs pSIR-PGK-GFP clone 12 increased in number approximately 3667-fold ± 315, went through 11.8 cell doublings, and spent a total of 112 days in vitro (DIV). After low-density expansion, the percentage of GFP-positive cells in the clone increased to 97% and the RFI remained relatively constant at 143.8. Figure 5b indicates the appearance of clone 12 after low-density plating in the same field under the fluorescein isothiocyanate (FITC) filter for GFP and with phase contrast microscopy. Note the appearance of small, round cells within the population. These results indicate that high levels of GFP expression can be maintained for long periods of time in vitro in a clonal population of cells transduced with the pSIR vector containing the PGK promoter. 
Figure 5 Long-term expression of GFP in a clonal population of rMSCs transduced with pSIR-PGK-GFP. (a) Flow cytometry of rMSCs pSIR-PGK-GFP clone 12 before (94 days in vitro (DIV)) and after low-density expansion (112 DIV). The percentage of GFP-expressing cells in the popu
TH expression and L-DOPA production in transduced rMSCs
For L-DOPA experiments, stably transduced rMSCs were analyzed for TH expression by immunostaining and Western analysis. rMSCs were not successfully transduced with pSIR-CMV-TIG. In Figure 6 , transduced rMSCs were immunostained with a primary antibody to TH and the signal was detected with a Texas-Red streptavidin conjugate. Cells were counterstained with DAPI to visualize nuclei. rMSCs transduced with the LXSN control virus did not express any detectable levels of TH (Figure 6a ). rMSCs transduced with pSIR-PGK-TIG were positive for TH by immunostaining (Figure 6c In order to obtain stable high-levels of L-DOPA generated from the pSIR vector, clones of cells were expanded from rMSCs transduced with pSIR-PGK-TIG. Isolated colonies of cells were screened for levels of TH expression by Western analysis (data not shown). A clone that expressed high levels of the TH transprotein was isolated (rMSCs pSIR-PGK-TIG clone 15). In Figure 6b , TH expression is observed in most of the cells within clone 15. rMSCs in clone 15 were replated at low-density and grown for an additional 2-3 weeks. Cells in the expanded clone appear as colonies. The expanded cells from clone 15 also expressed TH in the majority of cells within the population (Figure 6f) .
Figure 6 Stable expression of TH in transduced rMSCs by immunostaining and Western analysis. Transduced rMSCs were immunostained with a polyclonal antibody against TH (cytoplasmic) and counterstained with DAPI (nuclear). (a) Control rMSCs transduced with LXSN control virus; (b) A high TH-expressing clonal population of rMSCs transduced with pSIR-PGK-TIG (clone 15); rMSCs transduced with (c) pSIR-PGK-TIG, (d) LXSN-TIG, or (e) MSCV-TIG; (f) rMSCs pSIR-PGK-TIG
Transduced cells were also analyzed for the presence of TH in whole cell lysates by Western analysis. rMSCs transduced with the control LXSN virus had no endogenous TH (Figure 6g, lane 1) . rMSCs pSIR-PGK-TIG clone 15 expressed high levels of TH protein (Figure 6g , lane 2), and after expansion at low-density, continued to express high levels of TH (Figure 6g rMSCs transduced with TH alone do not spontaneously synthesize and secrete any L-DOPA due to the lack of the GC enzyme. 18 Levels of L-DOPA production were measured in the transduced rMSCs grown at high density and before low-density expansion. As indicated in construct closely paralleled amounts of TH expression seen by Western analysis (Figure 6g ).
Low-density expansion of L-DOPA-producing rMSCs
rMSCs stably transduced to produce L-DOPA with TH-IRES-GC were tested for their ability to undergo a massive expansion when plated at low density, as with GFPtransduced cells. As shown in Figure 7 , transduced rMSCs plated at low-density continued to synthesize L-DOPA at levels similar to rMSCs grown under high-density conditions: 424.8 ± 18.4 pmols/10 6 cells/h for LXSN-TIG, 263.5 ± 6.5 pmols/10 6 cells/h for pSIR-PGK-TIG, and 112.8 ± 17.3 pmols/10 6 cells/h for MSCV-TIG. Furthermore, the transduced rMSCs increased in number over 1000-fold in a period of 3-4 weeks (see Table 1 ).
The high L-DOPA-producing clonal population of rMSCs transduced with pSIR-PGK-TIG (clone 15) continued to synthesize high levels of L-DOPA (1096.0 ± 62.2 pmols/10 6 cells/h) after increasing in number nearly 2000-fold and spending approximately 3 months in vitro. The cells went through 10.9 cell doublings in the final 3-4 weeks of culture and maintained long-term production of L-DOPA, indicating the stability of the pSIR-PGK-TIG retrovirus in this population of cells.
Discussion
The results demonstrate that rMSCs can be transduced with a self-inactivating retrovirus containing a cellular promoter (PGK) to drive expression of either GFP or a bicistronic sequence encoding therapeutic enzymes, TH and GC, necessary for L-DOPA synthesis. Highly stable expression of transgenes driven by the pSIR vector can be obtained by isolating clonal populations of rMSCs. rMSCs stably transduced with retrovectors containing GFP or the bicistronic construct continued to express GFP or synthesize L-DOPA while undergoing at least a 1000-fold expansion in cell number by a single plating at low density.
The use of self-inactivating retroviruses in gene therapy is a relatively simple and effective way to integrate therapeutic DNA into a target cell genome and control expression of the transgene via an internal promoter of choice. Viral transcripts are not detected in target cells and therefore self-inactivating retroviruses appear to have a large measure of safety. 19 Recently, a self-inactivating lentiviral vector encoding glial-derived neuro- For each construct, the fold-increase in cell number and cell doublings after one low-density plating, and total days in vitro (DIV) from the start of the infection are shown. L-DOPA production in transduced rMSCs is shown in Figure 7 . Data represent means ± s.e.m. (n = 3).
Gene Therapy trophic factor (GDNF) driven by the PGK promoter was used in a rat model of PD. 24 In that study, in vivo expression of GDNF was exhibited for up to 14 weeks and no adverse effects of viral transduction on the host brain were observed.
In a previous study, human MSCs transduced with a bicistronic vector encoding GFP and a selectable marker exhibited long-term expression of both genes in vitro without any observed toxic effects to the MSCs. 25 Here, rMSCs transiently transfected with GFP downstream of the CMV and PGK promoters were able to express GFP (9% and 4% of cells, respectively). Similar relative patterns of reporter gene expression were seen when human MSCs were electroporated with constructs containing the chloroamphenicol acetyltransferase reporter gene controlled by either the CMV or PGK promoters. 26 The Phoenix amphotropic packaging system was used to both test expression of TH-IRES-GC or GFP in vectors and generate recombinant retrovirus in a short period of time. To date, helper virus production has not been detected in cells transduced with retroviruses produced in Phoenix cells. 27 The system seems safe for gene therapy. One special advantage of Phoenix cells is that viral supernatants can be collected from cells 2 days after transfection without the need for selection of the producer cells. Phoenix cells transfected with either pSIR-CMV-GFP or pSIR-CMV-TIG exhibited the highest amount of GFP expression or L-DOPA production, respectively. However, viral supernatants harvested from those cells were not able to transduce rMSCs, apparently because high levels of GFP or other transgenes can be toxic to some retroviral producer cells. 28 Phoenix cells transfected with the TH gene alone in the context of the MSCV promoter produced only one-fifth the amount of L-DOPA compared with cells transfected with both the TH and GC genes (TH-IRES-GC) in the same MSCV backbone, indicating the usefulness of the internal ribosome entry site in facilitating the production of both TH and GC from the same transcript and the necessity of GC in L-DOPA production.
When primary rMSCs were transduced with the retroviruses, higher levels of GFP expression were exhibited in cells transduced with pSIR-PGK-GFP and LXSN-GFP, reflecting the higher expression in rMSCs of genes driven by the PGK promoter and the MMLV LTR. Surprisingly, the MSCV LTR, which is highly active in embryonic stem cells and hematopoietic stem cells, 29 produced slightly lower levels of GFP expression in the adult rMSCs. Robust GFP expression was seen in a clonal population of rMSCs transduced with pSIR-PGK-GFP (clone 12). Stable GFP expression was observed in clone 12 for nearly 4 months in vitro, including expansion at low density.
L-DOPA production in the stably transduced rMSCs followed similar patterns as the rMSCs transduced with the GFP-containing constructs. rMSCs transduced with LXSN-TIG produced higher levels of secreted L-DOPA (283 pmols/10 6 cells/h), whereas rMSCs transduced with pSIR-PGK-TIG or MSCV-TIG secreted lower amounts of L-DOPA (approximately 90 pmols/10 6 cells/h for both). However, the highest levels of L-DOPA was observed in a clonal population of rMSCs transduced with pSIR-PGK-TIG (clone 15; 1096 pmols L-DOPA/10 6 cells/h). L-DOPA levels remained high in clone 15 after expansion at low density and nearly 3 months in vitro. The current results indicate that stable, high-level expression of a transgene can be accomplished in rMSCs by using a self-inactivating retrovirus system, where a nonviral cellular promoter is employed. This circumvents the use of a strong viral promoter, such as CMV, which can produce high-level expression in cells, but perhaps can elicit host immune responses that may lead to transgene shutdown.
An important aspect of this work is the finding that the problem of obtaining high yields of adult MSCs transduced to synthesize L-DOPA or other therapeutic products can be overcome by simply plating MSCs at low density. When rMSCs stably transduced with pSIR-PGK-TIG, LXSN-TIG and MSCV-TIG were plated at 3-6 cells/cm 2 , L-DOPA-producing cells increased in number over 1000-fold. MSCs plated at low density may exhibit an enormous potential for self-renewal while maintaining their multipotentiality.
17,30 L-DOPA-producing MSCs that have been plated at low density may also be better cells to engraft into the brain as they might resemble a more primitive state of the MSCs (see Ref. 17) . Furthermore, expansion of MSCs at low density for clinical purposes optimizes the number of therapeutic donor cells while minimizing time in the laboratory. The number of L-DOPA-producing MSCs transplanted into the striatum can be altered to target a known concentration of L-DOPA production. For PD patients, MSCs could be isolated easily from a small sample of their bone marrow, genetically engineered in culture to produce L-DOPA or other therapeutic products, and expanded to reach a trillion in number (theoretically). The appropriate number of therapeutic MSCs could then be transplanted into the striatum of the same PD patient.
Materials and methods
Construction of expression vectors P-CMV-GFP was constructed by ligating the 769 bp EcoRI-NotI fragment containing the gene for enhanced green fluorescent protein (eGFP from EGFP-1; Clontech, Palo Alto, CA, USA) to the EcoRI-NotI sites of PCIneo (Promega, Madison, WI, USA) P-PGK-GFP was made by ligating the 510 bp BglII-PstI (filled-in) fragment containing the PGK promoter from MSCVneo (Clontech) to the BglII-IpoI (851 bp) fragment of P-CMV-GFP from which the CMV promoter was removed. P-H4-GFP was made by ligating an 800 bp BamHI-EcoRV fragment containing the Histone4 promoter 20 to the BglII-IpoI fragment of P-CMV-GFP lacking the CMV promoter.
For the hTH-2 gene, a 1.5 kb sequence containing the cDNA for human tyrosine hydroxylase type 2 was amplified from LNCX-TH 15 (kindly provided by Dr UJ Kang, University of Chicago, Chicago, IL, USA) using the following primers: forward (For): 5′-cgcgatcgattccacactgagccatgcc-3′; reverse (Rev): 5′-gcgcgatatcctccgggacagtgcagac-3′. For all PCRs, the reactions were initially denatured at 95°C for 2 min, subjected to 30 cycles of 95°C for 1 min, 68°C for 30 s, and 73°C for 4 min, followed by a final extension at 73°C for 5 min. PFU polymerase (Stratagene, La Jolla, CA, USA) was used in all PCR reactions. The TH PCR product was digested with ClaI-EcoRV and cloned into the ClaI-EcoRV sites of pBluescript KS(pBS) (Stratagene) to obtain pBS-TH. For the rat GC gene, a 900 bp sequence was amplified from the vector p⌬gHCGC 15 (provided by Dr UJ Kang) containing the cDNA for rat GTP cyclohydrolase I using the following primers: for: 5′-cgcggaattcccaca ggtc acggccgcc-3′; rev: 5′-gcgcggatccgacaagtataccaactgg-3′. The PCR product was digested with EcoRI-BamHI and cloned into the EcoRI-BamHI sites of pBS to yield pBS-GC. The mouse phosphoglycerate kinase-1 promoter was obtained from the vector pPNT by amplifying a 511 bp sequence with the following primers: for: 5′-cgcgctcga gaattctaccgggtag-3′; rev: 5′-gcgcatcgataggtcgaaaggccc ggag-3′. The resultant PCR product was digested with XhoI-ClaI and cloned into the same sites of pBS to obtain pBS-PGK. Recombinant DNA was screened by restriction digest analysis and all positive clones were sequenced completely on an automated sequencer (Model 7700; ABI, Warrington, UK).
A bicistronic construct was made by first ligating the 900 bp EcoRI-XbaI fragment containing GC from pBS-GC and the 1.5 kbp NheI-EcoRI fragment containing TH from pBS-TH into the NheI-XbaI sites of PCIneo yielding PCIneo-THGC. PCIneo-THGC was then digested with EcoRV. The EcoRV-SmaI 900 bp fragment containing the encephalomyocarditis virus IRES from pIRESneo (Clontech) were ligated into the plasmid. The resultant vector was termed PCIneo-TH-IRES-GC. The central bicistronic construct of TH-IRES-GC is 3.4 kbp.
MSCV-GFP was made by ligating an 800 bp EcoRI-NotI (filled-in) fragment containing GFP cDNA from eGFP-1 to the EcoRI-HpaI sites of MSCVneo 31 (Clontech). MSCV-TH was made by ligating the 1.5 kbp ClaI (filled-in)-BamHI fragment from PCIneo-TH-IRES-GC containing only TH cDNA into the HpaI-BglII sites of MSCVneo. LXSN-GFP was made by ligating a BamHI fragment containing GFP cDNA into the same site in LXSN (Clontech). 32 MSCV-TH-IRES-GC and LXSN-TH-IRES-GC were constructed by standard techniques. A self-inactivating retroviral vector was obtained commercially (pSIR; Clontech). BamHI fragments containing either PGK-TH-IRES-GC, PGK-GFP, CMV-TH-IRES-GC, or CMV-GFP cassettes were subcloned into the BamHI site of pSIR and transformed (XL-10 Gold; Stratagene). Further details of plasmid construction are available upon request. All plasmids used for transfection were prepared with a plasmid kit (Maxiprep Kit; Qiagen, Valencia, CA, USA).
Isolation of primary rat MSCs
Primary cultures of rMSCs were obtained from the femurs and tibias of adult male Lewis rats (Harlan, Indianapolis, IN, USA) as described previously. 18 Briefly, rats were killed with a mixture of 70% CO 2 and 30% O 2 . Tibias and femurs were removed and placed on ice in complete medium containing minimal essential medium with alpha modification (␣-MEM; Gibco-BRL, Gaithersburg, MD, USA) with 20% fetal calf serum (Atlanta Biologicals, Norcross, GA, USA), 2 mm l-glutamine, penicillin (100 units/ml), streptomycin (100 g/ml), and amphotericin B (25 ng/ml; Mediatech, Herndon, VA, USA). Under sterile conditions, a 21-gauge needle attached to a 10-ml syringe filled with medium was used to flush out the marrow. Bone marrow was filtered through a 70 m nylon mesh and plated in a 75-cm 2 flask (Becton Dickinson, Franklin Lakes, NJ, USA). MSCs were isolated by their adherence to plastic. About 24 h after plating, non-adherent cells were removed and fresh medium was added. After the cells had grown to near confluency, they were passaged two to five times by being detached (0.25% trypsin/1 mm EDTA for 5 min) and replated at a density of around 5000 cells/cm 2 (highdensity conditions).
Transient transfection of rMSCs rMSCs were plated at passage 3 at a density of 5000 cells/cm 2 24 h before transfection in either six or 12-well plates. For 12-well plates (3.8 cm 2 ), 1 g of plasmid DNA was incubated with 6 l of a cationic lipid reagent (Geneporter; Gene Therapy Systems, San Diego, CA, USA) in 0.5 ml of reduced-serum medium (OPTI-MEM; Gibco-BRL). For six-well plates (9.6 cm 2 wells), 2 g of plasmid DNA and 12 l of GenePorter in 1 ml of OPTI-MEM were used. DNA and lipids were incubated in OPTIMEM at room temperature for 30 min and the transfection mixture was added to the rMSCs (500 l for 12-well dishes; 1 ml for six-well dishes). For control experiments, the PCIneo vector (Promega) alone was used in transfections. The transfection mixture/cells were incubated for 5 h at 37°C. After 5 h, an equal volume of complete medium containing 40% FCS was added to cells, yielding a final concentration of 20% FCS. The following day, fresh complete medium containing 20% FCS was added to the cells and cells were analyzed for GFP expression 72 h after the start of the transfection.
Analysis of GFP expression
After transfection, rMSCs were washed three times with phosphate-buffered saline (PBS, pH 7.4) and the GFP signal was analyzed with a fluorescent plate reader (Cytofluor II; PerSeptive Biosystems, Framingham, MA, USA) using a 485/20-nm excitation filter and a 530/30-nm emission filter. Cells were analyzed in triplicate, average fluorescent units were calculated, and then average background fluorescent units using the PCIneo transfection control were subtracted out.
For flow cytometry, cells were washed twice with PBS, trypsinized, and a single cell suspension was prepared for analysis (FACSVantage SE; Becton Dickinson, San Jose, CA, USA). The percentage of GFP-positive cells was calculated by measuring GFP with a 530 nm band pass filter after excitation with a 488 nm line of an argon laser. Propidium iodide was added to each sample to assess cell viability.
Transfection of Phoenix packaging cells
Phoenix amphotropic packaging cells 33 were obtained from the ATCC (Rockville, MD, USA) with permission of Dr G Nolan (Stanford University). Phoenix cells were transfected with retroviral vectors by calcium phosphate precipitation. 34 Briefly, 2.5 × 10 6 Phoenix cells were plated in 21.0 cm 2 plates in 5 ml of GM (10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 U/ml streptomycin, 2 mm l-glutamine in Dulbecco's modified Eagle's medium (DMEM)) 24 h before transfection. Just before transfection, the medium was changed to GM containing 25 m chloroquine. The transfection cocktail was prepared by adding 500 l 2 × Hepes buffered saline solution (50 mm HEPES, pH 7.05; 10 mm KCl; 12 mm dextrose; 280 mm NaCl; 1.5 mm Na 2 HPO 4 ) to 500 l of transfection mixture containing 10 g plasmid DNA in 240 mm CaCl 2 . The transfection cocktail was added to the Phoenix cells, the cells were incubated at 37°C for 10 h, and the medium was changed to fresh GM without chloroquine. GM was replaced 24 h before viral harvest, viral Gene Therapy supernatants were collected 48 h after the start of the transfection, filtered through a 0.45 m filter, and stored at −80°C for further use. Phoenix cells were analyzed at the time of viral harvest for GFP expression and L-DOPA production as described.
Transduction of rMSCs
About 100 000 rMSCs were plated the day before infection in 21.0 cm 2 plates. At the time of infection, day 1, 2.5 ml complete medium containing 20% heat-inactivated FCS was added to the cells in the presence of 500 l viral supernatant and 8 g/ml polybrene (Sigma, St Louis, MO, USA). The infection procedure was repeated 24 h later on day 2. On day 3, fresh complete medium was added with 20% FCS (not heat-inactivated). On day 4, cells were split 1:3 in 55.0 cm 2 plates in complete medium containing 200 g/ml G418 (Sigma) for a period of 14-21 days. The surviving cells were pooled and expanded for experiments by passaging cells between three and nine times.
Individual clones were isolated from pools of rMSCs transduced with either pSIR-PGK-GFP or pSIR-PGK-TIG by plating 100 cells/10-cm dish in the presence of G418. Approximately 20 individual colonies were selected from each construct with a cloning cylinder, and expanded into one well of a 24-well plate. After reaching 80% confluency, clones were subsequently expanded to one well of a 12-well plate. The process was repeated by growing clones in a six-well plate followed by a 10-cm dish. Highexpressing clones were screened by either fluorescence microscopy (pSIR-PGK-GFP) or by Western analysis for TH expression (pSIR-PGK-TIG) as described below. High-expressing clones for rMSCs transduced with either pSIR-PGK-GFP (clone 12) or pSIR-PGK-TIG (clone 15) were frozen down in 65% complete medium, 30% FCS, and 5% dimethylsulfoxide (DMSO) for use in future experiments.
For low density expansion experiments, MSCs beyond passage 6 were plated at 3-6 cells/cm 2 in medium containing 200 g/ml G418. The medium was replaced every 3-4 days, and cells were analyzed after 3-4 weeks in culture.
In vitro immunohistochemical staining
Cells were plated in one-well chamber slides (eight cells/cm 2 ). Cells were fixed with 4% paraformaldehyde for 20 min, blocked with 5% goat serum/0.4% Triton X-100 (Sigma) in PBS for 1 h, and immunostained with a polyclonal antibody against rat TH (Pel-freeze, Rogers, AZ, USA) at a dilution of 1:500 in blocking solution overnight at 4°C. The following day, a biotin-conjugated goat anti-rabbit secondary antibody (Vector Laboratories, Burlingame, CA, USA) was used at a dilution of 1:200 for 1 h. Cells were washed with PBS and incubated with a Texas-Red streptavidin (1:200; Vector Laboratories) for 20 min. Cells were washed and coverslipped with mounting medium containing 4′, 6-di-amidino-2-phenylindole (DAPI; Vector Laboratories).
Western analysis
To obtain whole cells lysates, cells were washed twice in PBS and then scraped in lysis buffer (1% v/v NP-40, 0.5% w/v sodium deoxycholate, 0.1% w/v SDS in PBS) containing a protease inhibitor cocktail (Protease Inhibitor Cocktail; Sigma) at a dilution of 1:100 to yield a final con-centration of the following protease inhibitors: 1.04 mm AEBSF, 0.8 m aprotinin, 0.021 mm leupeptin, 0.036 mm bestatin, 0.015 mm pepstatin A, and 0.014 mm E-64. The lysate was transferred to a 1.5 ml microcentrifuge tube, passed through a syringe with a 21-gauge needle three times, and kept on ice. The lysate was incubated on ice for 30 min, spun down in a centrifuge at 15 000 g for 20 min, and the supernatant was collected. For protein quantification, a protein assay kit (BioRad Protein Assay; BioRad, Hercules, CA, USA) was used. Fifteen g of whole cells lysate was loaded on to a 4-20% acrylamide gradient gel (BioRad). After electrophoresis, the gel was electroeluted on to nitrocellulose at 70 V for 1 h. After transfer, the membrane was blocked with 5% non-fat dry milk in PBS for 1 h, and incubated with 1:1000 rabbit polyclonal anti-TH diluted in TBS-T buffer (Tris-buffered saline, pH 8.0 with 0.05% Tween-20) overnight at 4°C. The following day, the blot was washed three times with TBS-T, incubated with 1:7500 HRP-labeled anti-rabbit secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted in TBS-T for 1 h, washed with TBS-T three times, and detected with ECL chemiluminescent detection reagents (Amersham Pharmacia Biotech, Piscataway, NJ, USA) on chemiluminescent film (Hyperfilm ECL, Amersham). The blot was then stripped with a solution of 100 mm 2-mercaptoethanol, 62.5 mm Tris-HCl, and 2% sodium dodecyl sulfate for 30 min at 50°C, washed with TBS-T, and reprobed as described above with an antibody to glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 1:10 000; Biodesign Int, Saco, ME, USA).
High pressure liquid chromatography (HPLC)
Cells were analyzed for L-DOPA production either after viral supernatant harvest (Phoenix cells) or after stable selection and expansion (rMSCs) as previously described. 18 Briefly, HPLC was performed on an octadecylsilane (C18) column with a mobile phase of 8.5% methanol in buffer (75 mm sodium phosphate, 10 m disodium EDTA, and 1.4 mm octane sulfonic acid, pH 2.90) Coulometric detection (CoulochemII 5100A; ESA, Bedford, MA, USA) was performed after sequential oxidation and reduction with the guard cell at a potential of 0.4 V, electrode 1 at −0.25 V, and electrode 2 at 0.35 V. The rMSCs were washed three times in PBS, placed in Earle's balanced salt solution (EBSS), and l-tyrosine (50 m) was added to the cells at t = 0. A sample of the medium was collected and added to 75 mm perchloric acid and assayed for L-DOPA. After the experiment, the cells were counted on a hemacytometer.
